Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

– STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing...

Related Keywords

Denmark ,Italy ,Bedford ,Massachusetts ,United States ,United Kingdom ,Cambridge ,Cambridgeshire ,American ,Edwardm Kaye , ,International Epilepsy Congress ,Company Annual Report On Form ,Augmentation Of Nuclear Gene Output Is Stoke ,Exchange Commission ,American Epilepsy Society ,Stoke Therapeutics Inc ,Acadia Pharmaceuticals ,Nasdaq ,Augmentation Of Nuclear Gene Output ,Stoke Therapeutics ,Chief Executive Officer ,Dominant Optic Atrophy ,Year To Date Financial ,Collaboration Agreement ,Autosomal Dominant Optic Atrophy ,Targeted Augmentation ,Nuclear Gene Output ,Private Securities Litigation Reform Act ,Annual Report ,Months Ended September ,Markets ,